Arcutis Biotherapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hi, I am Louise Chen, the largecap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Arcutis.
Arcutis is developing what we expect to be best-in-class in innovative topical dermatology therapies against validated biological targets in key areas of unmet need, including psoriasis and atopic dermatitis. The Company is led by a world-class leadership team that has overseen the preapproval of over 50 products by the US FDA.
Today we are very excited to have with us CEO Frank Watanabe and CMO Patrick Burnett to discuss Arcutis' pipeline and the market opportunity for its products. For investors that are hearing this story anew, can you please walk us through the history of the Company and how you came to be? And what do you see as the Company's differentiated offering in the years to come?
Sure. Nice to see you, Louise. We are about a four-year-old company, and we were really founded
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
